Nucleai
Business Services · Illinois, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
400 N Aberdeen St Ste 951, Chicago, Illi...Website
www.nucleai.aiRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Nucleai
Nucleai is a leading provider of AI-powered precision oncology technology transforming biomarker discovery and treatment decisions. Nucleai's platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies, licensing its research platform for internal use, and collaborating in biomarkers discovery projects.Explore more
Nucleai Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nucleai your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Nucleai, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Nucleai is spiking on competitors!
Funding: Get notified immidiatlly once Nucleai has new funding data
Check if Nucleai has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Nucleai launches new products
Congratulate Masked Content for being promoted to Masked Content at Nucleai
Website visits: Recent activity has been detected on your website
Click to see if Nucleai had a recent Job posting/layoffs
Earning: See what the market has to say on Nucleai recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Nucleai as Masked Content
Find 3 more new buyers
Compare Similar Companies to Nucleai
Compare insights from companies similar to Nucleai, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nucleai is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Nucleai is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Nucleai.
Nucleai financials insights
Gather financial insights about Nucleai, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$6.5M
2022
Series B
$33M
2024
Other Financing Round
$14M
Nucleai Tech Stack
A closer look at the technologies used by Nucleai
Most Recent Scoops
Event
Product Marketing, Events, Training, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Technology
Event
Product Marketing, Events, Software, Field /Outside Sales, Field Marketing, Healthcare Operations, Healthcare Technology
Partnership
Partnership, Product Development, Research & Development, Machine Learning, Software
Funding
Funding
Executive Move
Board of Directors
Nucleai News & Media
AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients. Bio-Techne's COMET™ platform and Nucleai's multimodal spatial...Nucleai to Showcase Expanded Suite of ADC Biomarker Scoring Solutions at ASCO 2025
CHICAGO--(BUSINESS WIRE)--Nucleai, an AI-powered spatial biomarker and diagnostics company, will showcase its expanded suite of solutions for antibody-drug conjugate (ADC) clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held this week from May 30-June 3 in Chicago, IL. Recent studies have demonstrated that AI-powered computational pathology and spatial biomarkers can predict ADC treatment response more accurately than standard pathological scores, enabliNucleai Launches First-of-its-Kind Deep Learning Model to Automate Spatial Proteomics, Accelerating Biomarker Discovery for ADCs, Bispecifics, and Immunotherapy
CHICAGO--(BUSINESS WIRE)--Nucleai, an AI-powered spatial biomarker and diagnostics company, today announced the launch of its deep learning model that automates the normalization of high-plex imaging data, a foundational step within the spatial proteomics workflow. Nucleai offers tools that support spatial profiling of protein expression and immune cell interactions, including cell architecture and neighborhoods, to support the development of antibody-drug conjugates (ADCs), bispecifics, and imNucleai Highlights AI-Powered Spatial Biomarker Breakthroughs to Enhance Immunotherapy Success for Lung and Skin Cancer Patients at SITC 2024
CHICAGO--(BUSINESS WIRE)--Nucleai, an AI-powered spatial biology company, will present two abstracts at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting. The presentations will detail how Nucleai's AI-driven spatial biomarker analysis provides actionable insights into patient treatment for non-small cell lung cancer (NSCLC) and melanoma, focusing on treatment resistance and patient stratification. Spatial biology examines the organization of cells and proteins in their natural
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Nucleai
Sign Up For FreeTo access detailed company insights
Nucleai is a leading provider of AI-powered precision oncology technology transforming biomarker discovery and treatment decisions. Nucleai's platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies, licensing... Read More
